Boditech Med Inc. (KOSDAQ:206640)
South Korea · Delayed Price · Currency is KRW 11,420
+280 (2.51%)
Apr 10, 2026, 3:30 PM KST
Boditech Med Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 162,093 | 138,160 | 134,219 | 118,077 | 157,708 | |
Revenue Growth (YoY) | 17.32% | 2.94% | 13.67% | -25.13% | 9.42% |
Cost of Revenue | 66,563 | 56,867 | 53,724 | 47,443 | 59,516 |
Gross Profit | 95,531 | 81,294 | 80,495 | 70,634 | 98,192 |
Selling, General & Admin | 41,698 | 33,337 | 30,836 | 26,370 | 24,177 |
Research & Development | 18,572 | 15,985 | 13,410 | 14,676 | 14,258 |
Amortization of Goodwill & Intangibles | 1,057 | 652.85 | 918.22 | 695.87 | 643.62 |
Other Operating Expenses | 1,098 | 996.87 | 972.66 | 837.56 | 800.56 |
Operating Expenses | 66,590 | 55,164 | 52,238 | 45,962 | 46,256 |
Operating Income | 28,940 | 26,129 | 28,257 | 24,671 | 51,936 |
Interest Expense | -411.34 | -352.5 | -350.39 | -203.92 | -196.5 |
Interest & Investment Income | 423.37 | 1,030 | 663.8 | 332.21 | 344.11 |
Earnings From Equity Investments | -1,398 | -497.3 | 251.47 | - | - |
Currency Exchange Gain (Loss) | -322.17 | 5,806 | 1,660 | 1,887 | 3,486 |
Other Non Operating Income (Expenses) | 909.17 | -229.66 | 711.81 | 568.61 | 1,106 |
EBT Excluding Unusual Items | 28,141 | 31,886 | 31,194 | 27,255 | 56,676 |
Gain (Loss) on Sale of Investments | 226.04 | 563.78 | 415.34 | -330.2 | -470.48 |
Gain (Loss) on Sale of Assets | -67.24 | -48.52 | -48.18 | 43.62 | -86.54 |
Asset Writedown | -519.24 | - | - | -35.86 | -79.44 |
Other Unusual Items | - | - | 6.01 | 32.8 | - |
Pretax Income | 27,781 | 32,401 | 31,567 | 26,965 | 56,039 |
Income Tax Expense | 3,901 | 5,181 | 4,899 | 1,684 | 8,644 |
Earnings From Continuing Operations | 23,880 | 27,220 | 26,668 | 25,281 | 47,395 |
Minority Interest in Earnings | -226.57 | 40.33 | -721.75 | -1,130 | -3,028 |
Net Income | 23,653 | 27,260 | 25,947 | 24,152 | 44,367 |
Net Income to Common | 23,653 | 27,260 | 25,947 | 24,152 | 44,367 |
Net Income Growth | -13.23% | 5.06% | 7.43% | -45.56% | -2.47% |
Shares Outstanding (Basic) | 22 | 22 | 22 | 22 | 23 |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 22 | 23 |
Shares Change (YoY) | -1.22% | -0.09% | -1.77% | -2.41% | -0.47% |
EPS (Basic) | 1091.00 | 1242.00 | 1181.10 | 1079.94 | 1937.17 |
EPS (Diluted) | 1091.00 | 1242.00 | 1181.00 | 1079.94 | 1936.26 |
EPS Growth | -12.16% | 5.17% | 9.36% | -44.23% | -2.01% |
Free Cash Flow | -10,932 | 13,452 | 29,695 | 7,808 | 31,697 |
Free Cash Flow Per Share | -504.22 | 612.87 | 1351.72 | 349.13 | 1383.14 |
Dividend Per Share | - | - | 200.000 | 150.000 | 200.000 |
Dividend Growth | - | - | 33.33% | -25.00% | - |
Gross Margin | 58.94% | 58.84% | 59.97% | 59.82% | 62.26% |
Operating Margin | 17.85% | 18.91% | 21.05% | 20.89% | 32.93% |
Profit Margin | 14.59% | 19.73% | 19.33% | 20.45% | 28.13% |
Free Cash Flow Margin | -6.74% | 9.74% | 22.12% | 6.61% | 20.10% |
EBITDA | 39,002 | 34,571 | 36,489 | 32,144 | 57,977 |
EBITDA Margin | 24.06% | 25.02% | 27.19% | 27.22% | 36.76% |
D&A For EBITDA | 10,062 | 8,442 | 8,232 | 7,473 | 6,041 |
EBIT | 28,940 | 26,129 | 28,257 | 24,671 | 51,936 |
EBIT Margin | 17.85% | 18.91% | 21.05% | 20.89% | 32.93% |
Effective Tax Rate | 14.04% | 15.99% | 15.52% | 6.24% | 15.43% |
Advertising Expenses | 2,286 | 1,768 | 1,149 | 962.7 | 686.79 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.